Articles related to MEDICAL MEETINGS AND EVENTS

The results of the WU-KONG6 study offer hope for NSCLC patients with EGFR exon20 insertion mutations, demonstrating the substantial antitumor efficacy of sunvozertinib.

The study findings suggest that acalabrutinib and rituximab, a chemo-free therapy option, may offer a new standard of care for older, untreated MCL patients, with promising early complete responses. Yet, more data is needed to understand long-term safety and risk of relapse.

FIL-ROUGE trial data presented at the International Conference on Malignant Lymphoma 2023 highlight the potential of intensified ABVD in improving outcomes for untreated Hodgkin lymphoma patients. Further exploration of this regimen’s long-term toxicity is anticipated.

Explore the groundbreaking findings from the TROPiCS-02 study, revealing sacituzumab govitecan as a potential game-changer in the treatment of endocrine refractory metastatic hormone receptor-positive breast cancer.

On July 11, 2023, participate in the AMCP PIE Webinar to learn more about the potential of VP-102, an investigational medication for molluscum contagiosum that is now undergoing FDA assessment.

Unpacking the landmark summit led by the American Pharmacists Association, it becomes clear that there is a pressing need and opportunity to expand healthcare coverage for pharmacists’ patient care services, promising substantial impacts on patient care and health systems.